U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

FAQS ABOUT MONOCLONAL ANTIBODIES FOR CONSUMERS

Contact the Combat COVID Monoclonal Antibodies Call Center:

1-877-332-6585

Therapeutics locator

Our bodies naturally make antibodies to fight infection. However, your body may not have antibodies that recognize a novel (or new) virus like the one that causes COVID-19. mAbs are made in a lab. The treatment helps boost your body’s ability to fight COVID-19. The mAb treatments do not replace the need for immunity from the COVID-19 vaccine, but they can help you if you are at risk for developing serious COVID-19 symptoms or severe outcomes. To find more information about current mAb treatment, visit https://aspr.hhs.gov/COVID-19/therapeutics/

mAb treatments authorized by the U.S. Food and Drug Administration (FDA) for emergency use may help people who are at high risk for serious symptoms of COVID-19 to:

  1. Reduce the likelihood of staying in the hospital.
  2. Recover faster from COVID-19.

mAbs are available for people who:

  1. Are at high risk of becoming seriously ill. To learn more, visit our page Who is at High Risk for Serious COVID-19?
  2. Have tested positive for COVID-19 and have mild to moderate symptoms of the disease for 7 days or less.
  3. Have been recently exposed to someone who has tested positive for COVID-19 and are at high risk for serious COVID-19.

mAb treatment must be given within 7 days of a person’s first symptoms of COVID-19 or having been exposed to someone who has tested positive for COVID-19. The sooner a person receives mAb treatment, the better.

mAb treatments are still being studied. However, mAb treatments have received Emergency Use Authorization (EUA) from the FDA and more than 600,000 people have been treated with mAbs. Researchers continue to study mAb treatments for safety and effectiveness.

Bebtelovimab is for people with mild to moderate COVID-19 symptoms and should be taken within 7 days of symptom onset.

Actemra® is for people in the hospital with worse COVID-19 symptoms.

Evusheld is a pre-exposure preventative mAb that is also approved for emergency use for people at high risk for serious COVID-19 infection. People who may be eligible to get Evusheld must not have tested positive or been exposed to COVID-19, but are considered at risk of having serious COVID-19 if they become infected.

REGEN-COV® (casirivimab and imdevimab) and bamlanivimab/etesevimab are no longer approved for emergency use. The FDA has deemed these two treatments ineffective against the Omicron variant, which is now the most common variant affecting people.

mAb treatments are given as either an IV infusion through your vein or as a series of shots.

mAb treatments offered to people who are not in the hospital are designed in a very similar way, with the same goal: to prevent the virus that causes COVID-19 from entering human cells.

The treatments are offered at thousands of infusion locations across the United States. These include infusion centers, urgent care clinics, and emergency rooms.

Different infusion locations have different amounts of the treatments and staff to give it available, so some locations may not be administering mAb treatments or may have limited stock of them. Your healthcare professional can help you find a location near you and can contact the infusion location to refer you for treatment.

You can learn more about mAb treatments on our page What Are Monoclonal Antibodies?

If you think you may qualify for mAb treatments and want to ask about getting treatment, contact your healthcare professional or call 1-877-332-6585 (English) and 1-877-366-0310 (Español) for more information.

Your healthcare professional may decide you do not qualify for mAb treatment. There could be several reasons for this. You may not meet all of the eligibility criteria or you may have an underlying health condition that disqualifies you for mAb treatment.

Whatever the reason is, do not give up. There may be other treatment options available such as oral antivirals. To explore more treatment options, please visit the Possible Treatment Options for COVID-19 page.

A mAb treatment does not replace the need for immunity from the COVID-19 vaccine, but can help you if you are at risk for developing serious COVID-19 symptoms or severe outcomes. Vaccination for COVID-19 is still recommended for most people. Talk with your healthcare provider for more information.